GlassScriptPhysician profile
Patrick R Kenny
NPI 1174509491
$11,283.14
in general payments reported to CMS, 2019-2025
36 companies · $2,537 in 2025
The $2,537 reported for 2025 was more than what 84% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,442 · 2020: $409 · 2021: $1,418 · 2022: $1,935 · 2023: $1,784 · 2024: $1,756 · 2025: $2,537.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,078.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,077.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,710.76 | 2019-2025 | |
| Janssen Biotech, INC. | $1,272.94 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $923.11 | 2019-2025 | Entyvio, Eohilia |
| Qol Medical, LLC | $681.96 | 2021-2025 | Sucraid, Sucraid |
| Ironwood Pharmaceuticals, INC | $636.09 | 2019-2025 | Linzess |
| Regeneron Healthcare Solutions, INC. | $589.19 | 2024-2025 | Dupixent |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $514.42 | 2019-2024 | Xifaxan |
| Daiichi Sankyo INC. | $512.05 | 2019-2023 | Injectafer |
| Celgene Corporation | $479.05 | 2021-2024 | Zeposia |
| Pfizer INC. | $348.73 | 2019-2025 | |
| Intercept Pharmaceuticals, INC. | $215.66 | 2020-2025 | Ocaliva |
| E.R. Squibb & Sons, L.L.C. | $195.16 | 2021-2023 | Zeposia |
| Covidien LP | $170.64 | 2019 | |
| Genzyme Corporation | $166.30 | 2019-2023 | |
| Phathom Pharmaceuticals, INC. | $164.52 | 2024-2025 | Voquezna |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $158.06 | 2023-2025 | Ibsrela |
| Aimmune Therapeutics, INC. | $143.87 | 2024-2025 | Zenpep |
| Merck Sharp & Dohme LLC | $136.61 | 2019-2023 | Dificid |
| Davol INC. | $130.30 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $127.27 | 2024-2025 | Iqirvo |
| Neuraxis, INC. | $123.63 | 2025 | |
| Ucb, INC. | $121.14 | 2019-2020 | |
| Ferring Pharmaceuticals INC. | $108.92 | 2019-2021 | |
| Nestle Healthcare Nutrition INC. | $108.35 | 2021-2023 | |
| Gilead Sciences, INC. | $107.88 | 2024-2025 | |
| Shionogi INC | $83.75 | 2019 | |
| Lilly USA, LLC | $68.29 | 2023-2025 | Omvoh |
| Braintree Laboratories, INC. | $64.95 | 2019-2023 | Suflave |
| Shire North American Group INC | $54.37 | 2019 | |
| Blueprint Medicines Corporation | $39.63 | 2024-2025 | Ayvakit |
| Medtronic, INC. | $39.61 | 2024-2025 | Gi Genius, Pillcam |
| Amgen INC. | $20.70 | 2021 | |
| Ionis Pharmaceuticals, INC. | $20.52 | 2025 | Tryngolza |
| Madrigal Pharmaceuticals | $17.71 | 2025 | Rezdiffra |
| Novo Nordisk INC | $15.15 | 2025 | Wegovy |
| Mallinckrodt Hospital Products INC. | $11.85 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Kenny listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.